EZH2 and hepatocellular carcinoma: The results showed that levels of most of the immunosuppressive cytokines, such as Arg2, CCL28, DNMT1, and EZH2, were upregulated in the high-risk subtype (Figure 8C), suggesting that high-risk A-HCC patients have reduced cancer-immunity cycle activity.